Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021

Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will release its financial results for Q2 2021 on August 9, 2021, after market close. A conference call will follow at 4:30 PM ET, where investors can discuss the results. The company specializes in mRNA medicines and vaccines aimed at infectious diseases and rare conditions affecting the liver and respiratory system. Arcturus utilizes advanced technologies like LUNAR® lipid-mediated delivery and STARR™ mRNA Technology, featuring a pipeline that includes candidates for SARS-CoV-2 and Influenza vaccines.

Positive

• Diverse pipeline of RNA therapeutics, including vaccines for COVID-19 and Influenza.
• Advanced mRNA technologies such as LUNAR® and STARR™ enhancing drug delivery.
• Established collaborations with major pharmaceutical companies and organizations.

Negative

• None.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the second quarter ended June 30, 2021 after the market close on Monday August 9, and will also host a conference call and webcast at 4:30 pm Eastern Time on August 9, 2021.

Monday, August 9th @ 4:30 p.m. ET

Domestic: 877-407-0784

International: 201-689-8560

Conference ID: 13721797

Webcast: http://public.viavid.com/index.php?id=145873

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, and Cystic Fibrosis along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (222 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005727/en/

FAQ

When will Arcturus Therapeutics release its Q2 2021 financial results?

Arcturus Therapeutics will release its Q2 2021 financial results on August 9, 2021, after market close.

What time is the Arcturus Therapeutics conference call?

The conference call for Arcturus Therapeutics is scheduled for 4:30 PM ET on August 9, 2021.

What is the focus of Arcturus Therapeutics?

Arcturus Therapeutics focuses on developing mRNA medicines and vaccines for infectious diseases and rare liver and respiratory diseases.

What technologies does Arcturus Therapeutics use?

Arcturus uses advanced technologies such as LUNAR® lipid-mediated delivery and STARR™ mRNA Technology.

What products are in Arcturus Therapeutics' pipeline?

Arcturus has a pipeline that includes mRNA vaccine candidates for SARS-CoV-2 and Influenza, as well as treatments for conditions like OTC Deficiency and Cystic Fibrosis.